Tenderwize
Wróć do wyszukiwania

Open house drug discount agreements multienzyme (Lipase, Protease etc.), ATC A09AA02

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Feb 03, 2028 · 523 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Multienzyme (Lipase, Protease etc.), ATC A09AA02

50/100

Ocena szansy

Needs reviewLow complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

50 / 100

Złożoność

25 / 100

Czynniki ryzyka

No guaranteed sales; actual revenue depends on prescription volumes and market penetration.

Monthly cut-off deadlines require careful timing; missing the 3rd may delay contract start by up to two months.

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Mar 2028
  • Non-exclusive drug discount agreements for multienzyme products (ATC A09AA02) with AOK Bayern.
  • Open-house model: all eligible pharmaceutical companies may join on identical terms.
Pokaż pełne podsumowanie

Open-house model for non-exclusive drug discount agreements (Rabattverträge) for multienzymes (Lipase, Protease etc.), ATC A09AA02, with AOK Bayern. The procedure is not a competitive tender but a continuous open-house where any eligible pharmaceutical company can enter identical, non-negotiable agreements. The contract term is from 1 April 2026 to 31 March 2028, with possible early termination if superseded by regular discount contracts. There is no estimated value, and no award criteria since all eligible participants are accepted. The key eligibility requirement is a signed declaration of reliability. Submissions can be in paper (two copies) or electronically with a qualified electronic signature.

Ryzyka

No guaranteed sales; actual revenue depends on prescription volumes and market penetration.

Monthly cut-off deadlines require careful timing; missing the 3rd may delay contract start by up to two months.

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Eligibility

  • Only pharmaceutical companies are eligible to participate.

Administrative

  • Signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.
  • Contract and annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be signed and submitted in duplicate (paper) or with qualified electronic signature.

Wymagania mogą być niepełne.

Zamawiający

Lokalizacja

München, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE811695320

Działalność

Health

Części (1)

LOT-0001

Open house drug discount agreements multienzyme (Lipase, Protease etc.), ATC A09AA02

Non-exclusive discount agreements for pharmaceutical products containing multienzymes (Lipase, Protease etc.), ATC A09AA02. The agreement is open to all pharmaceutical companies meeting the eligibility criteria. Contracts start on the first of the month following complete submission, with a monthly cut-off on the 3rd. The latest joining date is 3 February 2028.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

DE212, Germany

Czas trwania

Mar 2026 - Mar 2028

Kategoria

Pharmaceutical products

Termin

Deadline Feb 03, 2028

Szczegóły zamówienia

Data publikacji
15 Feb 2026
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
107164-2026

Dokumenty (2)

Dokument zamówienia 1Portal składania ofert 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30